Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

By R. Advani, J. Buggy, J. Sharman, Sonali M. Smith, T. Boyd, B. Grant, K. Kolibaba, R. Furman, S. Rodríguez, B. Chang and 5 more. Journal of Clinical Oncology, 2013

1,107 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/e216ba7f2393ae2f8a98b7bfc7105f12b94630e6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Simar Pal Singh
2. Floris Dammeijer
3. R. Hendriks
4. J. Woyach
5. Ta-Ming Liu
6. S. Jaglowski
7. N. Muthusamy
8. J. Dubovsky

Citations in the corpus

• Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia (2015, neutral): “Upper respiratory tract infection 56 (48) 1 (1)”
• Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. (2013, background): “Irreversible ITK binding, ITK signal inhibition, and Th1-skewed cytokine patterns were also identified in CLL patients treated with ibrutinib in 2 clinical trials.(37,38) These findings were validated using a well-established mouse model of cutaneous leishmaniasis, and further clinical relevance was”
• Role of Bruton’s tyrosine kinase in B cells and malignancies (2018, background): “Importantly, both in CLL and MCL ibrutinib treatment induces a redistribution lymphocytosis, a transient rise of leukemic cells in the circulation and a concomitant rapid reduction of these cells at the affected tissue sites.”